Portal de investigación
Estudio observacional para evaluar la adherencia a TREMFYA® (guselkumab) en la práctica clínica en pacientes con psoriasis moderada a grave.
Datos básicos
- Protocolo:
- CNTO1959PSO4024
- EUDRACT:
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Año de incio:
- 2023
- Año de finalización:
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
[[Translated article]]Improving the Management and Follow-up of Atopic Dermatitis: A Delphi Process Report of Consensus Between Hospital Dermatologists and Pharmacists.
Herranz-Pinto P; (...); Tortajada Goitia B
Practice Guideline. 10.1016/j.ad.2023.07.008. 2023
[Translated article] Cybersecurity: a priority for pharmacy services in the age of artificial intelligence
Marin, Cayetano M. Hernandez, Monte-Boquet, Emilio, Andres, Jose Luis Poveda
Editorial Material. 10.1016/j.farma.2024.08.009. 2024
[Translated article] Checklist for the pharmaceutical care of patients with interstitial lung disease (CheckEPID): A Delphi-based consensus.
Calvin-Lamas, Marta; (...); Ventayol Bosch, Pere
Article. 10.1016/j.farma.2023.09.004. 2023
[Translated article] Good humanisation practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Andrés JLP, Solsona MDE
Article. 10.1016/j.farma.2023.10.004. 2024
[Translated article] National registry and analysis of pharmaceutical interventions in critical care units: PHARMACRITIC study.
Cerezuela, Maria Martin; (...); Chiva, Esther Domingo
Article. 10.1016/j.farma.2024.10.003. 2024
[Translated article] New challenges in advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2024.05.001. 2024
[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.
Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.12.007. 2025
[Translated article] Real-world effectiveness and safety of nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma.
Fernandez, Laura Lorente; (...); Andres, Jose Luis Poveda
Article. 10.1016/j.farma.2024.09.006. 2024
2022 update of the indicators for quality of care and pharmaceutical care for people living with human immunodeficiency virus.
Martin Conde MT; (...); Morillo-Verdugo, Ramon
Article. 10.1016/j.farma.2023.04.008. 2023
2022 update of the indicators for quality of care and pharmaceutical care for people living with human immunodeficiency virus.
Martin, Maria Teresa; (...); Morillo-Verdugo, Ramon
Article. 10.1016/j.farma.2023.01.007. 2023
A Qualitative Tool to Guide in the Interpretation of the Numerical Rating Scale for Pruritus Intensity in Patients with Atopic Dermatitis.
Figueras I; (...); Ortiz de Frutos FJ
Article. 10.2340/actadv.v104.18255. 2024
Activities of the clinical pharmacist in the intensive care units.
Becerril-Moreno F; (...); Cobo-Sacristán S
Article. 10.1016/j.farma.2024.09.004. 2024
Analysis of the situation of pharmaceutical care for patients with immune-mediated inflammatory diseases before and after the COVID-19 pandemic.
Lopez Sanchez, Piedad; (...); Monte Boquet, Emilio
Article. 10.1016/j.farma.2024.10.001. 2024
Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA).
Pereyra-Rodríguez JJ; (...); Ortiz de Frutos FJ
Letter. 10.1111/jdv.19432. 2023
Cefiderocol pharmacokinetics in critically ill patients undergoing ECMO support.
Marín-Cerezuela M; (...); Ramirez P
Letter. 10.1186/s13054-024-05126-4. 2024
Consensus statement on the use of biosimilar drugs in immune-mediated diseases in Spain
Monte-Boquet, Emilio; (...); Sellas, Agusti
Article. 10.1016/j.reuma.2022.12.001. 2023
COST-EFFECTIVENESS ANALYSIS OF DIFELIKEFALIN FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE ASSOCIATED-PRURITUS IN SPAIN
Sanchez-Alvarez, Emilio E.; (...); Hernaez Colque, M.
Meeting Abstract. 2024
Cybersecurity, a priority for pharmacy services in the age of artificial intelligence.
Hernández Marín CM, Monte-Boquet E, Poveda Andrés JL
Editorial Material. 10.1016/j.farma.2024.08.001. 2024
Checklist for Pharmaceutical Care of the Patient with interstitial lung disease (CheckEPID): A Delphi-based consensus.
Calvin Lamas M; (...); Ventayol Bosch P
Article. 10.1016/j.farma.2023.06.010. 2023
Determining value in the treatment of activated PI3Kdelta syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders.
Abad, Maria Reyes; (...); Gil, Alicia
Article. 10.33393/grhta.2024.3041. 2024
Determining what represents value in the treatment of prurigo nodularis and its key unmet needs in Spain through Multi-Criteria Decision Analysis
Silvestre, Juan Francisco; (...); Serra-Baldrich, Esther
Article. 10.1002/jvc2.275. 2024
Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.
Megias-Vericat, J E; (...); Poveda Andres, J L
Letter. 10.1016/j.thromres.2024.109122. 2024
Elevating the Standard of Care for Patients with Psoriatic Arthritis: 'Calls to Action' from a Multistakeholder Pan-European Initiative.
Verbinnen I; (...); Helliwell PS
Article. 10.1007/s40744-024-00664-3. 2024
Extravasation of monoclonal antibodies commonly used in oncology: Classification, management and the role of the pharmacist.
Bauters T, Clottens N, Albert-Marí MA
Article. 10.1177/10781552231178674. 2023
Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; (...); Moret-Tatay I
Article. 10.3390/ijms25073717. 2024
Hereditary angioedema in Spain: medical care and patient journey.
Caballero, Teresa; (...); Zamora, Carolina
Article. 10.1186/s13023-024-03182-1. 2024
Improving the Management and Follow-up of Atopic Dermatitis: A Delphi Process Report of Consensus Between Hospital Dermatologists and Pharmacists.
Herranz-Pinto P; (...); Tortajada Goitia B
Practice Guideline. 10.1016/j.ad.2023.04.019. 2023
Inhaled aztreonam lysine in the management of Pseudomonas aeruginosa in patients with cystic fibrosis: real-life effectiveness.
Jimenez-Lozano, Ines; (...); Alvarez-Fernandez, Antonio
Article. 10.1136/ejhpharm-2023-003937. 2023
Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis.
Pozo-Rosich P; (...); Irimia P
Article. 10.1186/s10194-024-01747-w. 2024
Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
Martin-Cerezuela, Maria; (...); Ramirez Galleymore, Paula
Article. 10.3390/antibiotics13080706. 2024
New challenges of advanced therapies.
Megías-Vericat JE; (...); Poveda Andrés JL
Article. 10.1016/j.farma.2023.11.008. 2024
Omics-Based Approaches for the Characterization of Pompe Disease Metabolic Phenotypes
Gomez-Cebrian, Nuria; (...); Puchades-Carrasco, Leonor
Review. 10.3390/biology12091159. 2023
OPTIMIZING MANAGEMENT AND OUTCOMES OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS) IN SPAIN: BEWAYAPDS PROJECT
Flores-Moreno, S.; (...); Gil, A.
Meeting Abstract. 2024
Patient-reported outcome measures in severe asthma: an expert consensus.
Martínez-Moragón E; (...); Sánchez-Cuellar S
Article. 10.1080/02770903.2023.2297372. 2023
Pharmacist care in hospital emergency departments: a consensus paper from the Spanish hospital pharmacy and emergency medicine associations
Ramos, Jesus Ruiz; (...); Marco, Javier Povar
Article. 2023
Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.
Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis
Article. 10.3390/ijms26041760. 2025
Presence of good humanization practices in the healthcare of patients with rare diseases in Pharmacy Services
Company Albir MJ, Poveda Andrés JL, Edo Solsona MD
Article. 10.1016/j.farma.2023.06.0131130. 2024
Telematic Interview in Telepharmacy: a comprehensive guide for pharmacotherapeutic follow-up and and informed drug delivery.
Barbadillo-Villanueva S; (...); Monte-Boquet E
Article. 10.1016/j.farma.2024.04.008. 2024
Telematic interview in telepharmacy: consensus document for farmacotherapeutic monitoring and informed drug delivery.
Barbadillo-Villanueva S; (...); Monte-Boquet E
Article. 10.1016/j.farma.2024.01.006. 2024
TELEPROM Psoriasis: Enhancing patient-centered care and health-related quality of life (HRQoL) in moderate-to-severe plaque psoriasis.
Mercadal-Orfila G; (...); Herrera-Pérez S
Article. 10.3389/fmed.2024.1465725. 2024
The value of the reflective discussion in decision-making using multi-criteria decision analysis (MCDA): an example of determining the value contribution of tabelecleucel for the treatment of the Epstein Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Badia, Xavier; (...); Valles, Joan-Antoni
Article. 10.1186/s13023-024-03324-5. 2024
Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.
Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis
Article. 10.1136/ejhpharm-2024-004184. 2024
VALUE CRITERIA FOR OUTCOMES BASED MANAGED ENTRY AGREEMENT OF CAR-T IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) THROUGH MCDA
Poveda, J. L.; (...); Lizan, L.
Meeting Abstract. 2023